Cancer T cell immunotherapy with bispecific antibodies and chimeric antigen receptors

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 239-254

  Lacher, Markus D ^a   Provenzano, Maurizio ^b  

^a T cell Therapeutics Inc   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antibody; Bispecific; BiTE; Cancer; CAR; scFv; taFv

Indexed keywords

BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN; CATUMAXOMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHIMERIC PROTEIN; EPHRIN RECEPTOR A2; EPITHELIAL CELL ADHESION MOLECULE; MT 110; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEOCHONDROITIN SULFATE; SOLITOMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; DRUG CROSS REACTIVITY; FOLLOW UP; HUMAN; IMMUNOGENICITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REMISSION; T LYMPHOCYTE; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, BISPECIFIC; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PATENTS AS TOPIC; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84888020881     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748928113088880003     Document Type: Article

References (156)

1. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23): 10946-51.
2. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumourinitiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2011; 2: 162.
3. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011; 2011: 941876.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7): 3983-8.
5. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22(3): 457-72.
6. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108(19): 7950-5.
7. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5(9): 744-9.
8. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1(3): 306-15.
9. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3(95): 95ra73.
10. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116(20): 4099-102.
11. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321(5891): 974-7.
12. Cooper LJ, Jena B, Bollard CM. Good T cells for bad B cells. Blood 2012; 119(12): 2700-2.
13. Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep 2003; 10(6): 2005-8.
14. Bubenik J. MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 2005; 51(1): 1-2.
15. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011; 45: 341-60.
16. Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology 2012; 1(6): 863-73.
17. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical perspective. Pharmacol Ther 2012; 136(3): 334-42.
18. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365(8): 725-33.
19. Urba WJ, Longo DL. Redirecting T cells. N Engl J Med 2011; 365(8): 754-7.
20. Chames P, Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? MAbs 2009; 1(6): 539-47.
21. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006; 12(2): 569-76.
22. Grosse-Hovest L, Muller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101(18): 6858-63.
23. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, et al. Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res 2011; 71(9): 3175-81.
24. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges. Cancer Immunol Immunother 2012; 61(7): 953-62.
25. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21(2): 215-23.
26. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18(2): 465-74.
27. Cioffi M, Heeschen C. Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease? Oncoimmunology 2012; 1(4): 560-2.
28. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013. http://dx. doi. org/10. 1016/j. cbpa. 2013. 03. 029.
29. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69(14): 5627-9.
30. European Association of Pharma Biotechnology website (Patrick A. Baeuerle. BiTE, a New Antibody Platform; October 6, 2009; Hannover). Available at: http://www. eapb. org/fileadmin/Attachement/events09/Patrick_Bae uerle_Micromet. pdf. (Accessed on: May 19, 2013).
31. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43(8): 1129-43.
32. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4(2).
33. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117(17): 4542-51.
34. Riethmuller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012; 12: 12.
35. McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 2012; 8(6): 687-95.
36. Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics 2013; 10(1): 1-18.
37. Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G, et al. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol 2000; 165(2): 888-95.
38. Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, et al. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002; 169(1): 137-44.
39. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998; 77(5): 763-72.
40. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90(14): 6444-8.
41. Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26(1): 1-9.
42. Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282(17): 12650-60.
43. Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M, et al. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): The case of the hEx3 diabody. J Biol Chem 2011; 286(3): 1812-8.
44. Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284(38): 25612-9.
45. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69(12): 4941-4.
46. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95(6): 2098-103.
47. Kufer, P., Lutterbuse, R., Kohleisen, B., Zeman, S., Bauerle, P. Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders. US7635472 (2009).
48. Sharma, M. S., Shah, A., Hammond, S. Protein formulation. US20100303827 (2010).
49. Nagorsen, D., Kufer, P., Zugmaier, G., Baeuerle, P. Dosage regimen for administering a CD19xCD3 bispecific antibody. WO2011051307 (2011).
50. Kufer, P., Raum, T., Kischel, R., Lutterbuese, R., Hoffmann, P., Rau, D., Klinger, M., Mangold, S., Bluemel, C. Cross-speciesspecific PSCAxCD3, CD19xCD3, c-MetxCD3, EndosialinxCD3, EpCAMxCD3, IGF-1RxCD3 or FAPalphaxCD3 bispecific single chain antibody. US20120034228 (2012).
51. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92(15): 7021-5.
52. Lanzavecchia, A. Potent T cell modulating molecules. US7820166 (2010).
53. Zugmeier, G., Kufer, P., Rüttinger, D., Kaubitzsch, S. Dosage regimen for administering an EpCAMxCD3 bispecific antibody. WO2011033105 (2011).
54. Kufer, P., Berry, M., Offner, S., Brischwein, K., Wolf, A., Raum, T., Kohleisen, B., Lenkkeri-Schutz, U., Baeuerle, P. Pharmaceutical composition comprising a bispecific antibody for EpCAM. US7919089 (2011).
55. Kufer, P., Lenkkeri-Schütz, U., Lutterbüse, R., Kohleisen, B. Less immunogenic binding molecules. US8101722 (2012).
56. Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One 2012; 7(5): e36412.
57. Kufer, P., Raum, T., Kischel, R., Lutterbüse, R., Hoffmann, P., Rau, D., Mangold, S., Klinger, M., Schaller, E., Hausmann, S., Fluhr, P., Steiger, C. Cross-species-specific PSMAxCD3 bispecific single chain antibody. WO2010037836 (2010).
58. Kufer, P., Raum, T., Kischel, R., Lütterbuse, R., Hoffmann, P., Rau, D., Mangold, S., Klinger, M., Aschaller, E., Hausmann, S., Fluhr, P., Steiger, C. Cross-species-specific PSMAxCD3 bispecific single chain antibody. US20110293619 (2011).
59. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010; 59(8): 1197-209.
60. Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, et al. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 2011; 34(8): 597-605.
61. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res 2007; 67(8): 3927-35.
62. Hammond, S. A., Kiener, P. A., Bruckheimer, E., Kinch, M. S., Roff, S., Lutterbuese, R., Lutterbuese, P., Schlereth, B., Baeuerle, P. A., Kufer, P. EphA2 BiTE molecules and uses thereof. US20080044413 (2008).
63. Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012; 11(12): 2664-73.
64. + T cells. J Immunol 2012; 189(6): 3249-59.
65. Mack, M., Schlondorff, D., Spring, M. Bispecific antibody and chemokine receptor constructs. US6723538 (2004).
66. Hofmeister, R., Kohleisen, B., Lenkkeri-Schütz, U., Itin, C., Bäuerle, P., Carr, F. J., Hamilton, A. A., Williams, S. Multispecific deimmunized CD3-binders. US8076459 (2011).
67. + T cells during activation. J Immunol 2000; 164(9): 4493-9.
68. Ward SG. CD28: A signalling perspective. Biochem J 1996; 318 (Pt 2): 361-77.
69. + T cell-mediated tumor eradication. Mol Ther 2010; 18(2): 413-20.
70. Macian F, Im SH, Garcia-Cozar FJ, Rao A. T-cell anergy. Curr Opin Immunol 2004; 16(2): 209-16.
71. Jung, G. Bispecific antibody molecule. US7538196 (2009).
72. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33(5): 1334-40.
73. Grosse-Hovest L, Wick W, Minoia R, Weller M, Rammensee HG, Brem G, et al. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cellmediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 2005; 117(6): 1060-4.
74. + lymphoider Neoplasien. PhD Thesis, Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany, 2008.
75. Otz T, Grosse-Hovest L, Hofmann M, Rammensee HG, Jung G. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009; 23(1): 71-7.
76. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific singlechain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43(6): 763-71.
77. Rader C. DARTs take aim at BiTEs. Blood 2011; 117(17): 4403-4.
78. Moran N. Boehringer splashes out on bispecific antibody platforms. Nat Biotechnol 2011; 29(1): 5-6.
79. Munro TP, Mahler SM, Huang EP, Chin DY, Gray PP. Bridging the gap: Facilities and technologies for development of early stage therapeutic mAb candidates. MAbs 2011; 3(5): 440-52.
80. Petering J, McManamny P, Honeyman J. Antibody therapeutics-the evolving patent landscape. N Biotechnol 2011; 28(5): 538-44.
81. Portner LM, Schonberg K, Hejazi M, Brunnert D, Neumann F, Galonska L, et al. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD16. Cancer Immunol Immunother 2012; 61(10): 1869-75.
82. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 2013; 21(4): 895-903.
83. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108(27): 11187-92.
84. Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25(10): 551-9.
85. Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, et al. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS One 2013; 8(4): e61953.
86. Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25(10): 571-80.
87. Bruenker, P., Fauti, T., Jaeger, C., Klein, C., Umana, P. Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use. US20130058936 (2013) & WO2013026839 (2013).
88. Auer, J., Bruenker, P., Fauti, T., Jaeger, C., Klein, C., Schaefer, W., Sustmann, C., Umana, P. Bispecific antigen binding molecules. WO2013026831 (2013).
89. Ast, O., Bruenker, P., Fauti, T., Freimoser-Grundschober, A., Jaeger, C., Klein, C., Moessner, E., Umana, P. Bispecific T cell activating antigen binding molecules. WO2013026833 (2013).
90. Bruenker, P., Jaeger, C., Klein, C., Schaefer, W., Umana, P. Fc-free antibodies comprising two Fab fragments and methods of use. WO2013026835 (2013).
91. Ast, O., Fauti, T., Jaeger, C., Klein, C., Umana, P. Bispecific T cell activating antigen binding molecules. WO2013026837 (2013).
92. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90(2): 720-4.
93. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibodytype specificity. Proc Natl Acad Sci USA 1989; 86(24): 10024-8.
94. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993; 178(1): 361-6.
95. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55(15): 3369-73.
96. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "Are we nearly there yet?". Hum Gene Ther 2009; 20(11): 1229-39.
97. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010; 2010: 956304.
98. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18(4): 843-51.
99. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18(4): 666-8.
100. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70(22): 9053-61.
101. Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011; 2: 378-82.
102. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, et al. T cell-encoded CD80 and 4-1BBL induce auto-and transcostimulation, resulting in potent tumor rejection. Nat Med 2007; 13(12): 1440-9.
103. Sadelain, M., Stephan, M. Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes. US8389282 (2013).
104. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14(11): 1264-70.
105. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptorpositive T cells in patients with neuroblastoma. Blood 2011; 118(23): 6050-6.
106. + cytotoxic T cells exert tumor-specific effector function. Cancer Res 2007; 67(17): 8335-43.
107. Hwu, P., Kershaw, M. H., Rosenberg, S. A. Activated dual specificity lymphocytes and their methods of use. US7723111 (2010).
108. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005; 106(5): 1544-51.
109. Zhang, T., Sentman, C. L. Chimeric NK receptor and methods for treating cancer. US7994298 (2011).
110. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res 2011; 71(6): 2066-76.
111. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4(132): 132ra53.
112. Jensen, M. Method and compositions for enhanced anti-tumor effector functioning of T cells. US20120148552 (2012) & WO2010025177 (2010).
113. Capon, D. J., Smith, D. H., Tian, H., Winslow, G. A., Siekevitz, M. Multispecific chimeric receptors. US6103521 (2000).
114. Eshhar, Z., Gross, G., Waks, T. Endowing lymphocytes with antibody specificity. US5906936 (1999) & US5912172 (1999).
115. Capon, D. J., Weiss, A., Irving, B. A., Roberts, M. R., Zsebo, K. Chimeric chains for receptor-associated signal transduction pathways. US5359046 (1994) & US6407221 (2002).
116. Eshhar, Z., Schindler, D., Waks, T., Gross, G. Chimeric receptor genes and cells transformed therewith. US7741465 (2010).
117. Capon, D. J., Weiss, A., Roberts, M. R., Zsebo, K. Chimeric chains for receptor-associated signal transduction pathways. US6319494 (2001).
118. Capon, D. J., Tian, H., Smith, D. H., Winslow, G. A., Siekevitz, M. Chimeric receptors comprising Janus kinase for regulating cellular pro liferation. US5741899 (1998).
119. Roberts, M. R. Chimeric receptor molecules for delivery of costimulatory signals. US5712149 (1998).
120. Seed, B., Romeo, C., Kolanus, W. Redirection of cellular immunity by receptor chimeras. US5843728 (1998).
121. Seed, B., Banapour, B., Romeo, C., Kolanus, W. Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells. US5851828 (1998).
122. Seed, B., Romeo, C., Kolanus, W. Redirection of cellular immunity by protein(-)tyrosine kinase chimeras. US5912170 (1999) & US6004811 (1999).
123. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009; 32(7): 689-702.
124. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 2011; 129(12): 2935-44.
125. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17(8): 1453-64.
126. Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1(9): 1577-83.
127. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: Current understanding and future directions. J Gene Med 2012; 14(6): 405-15.
128. Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells. Tissue Antigens 2009; 74(4): 277-89.
129. Patent Lens website. Available at: http://www. patentlens. net/. (Accessed on: May 19, 2013).
130. Wang K, Wei G, Liu D. CD19: A biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1(1): 36.
131. Jensen, M. C., Forman, S., Raubitschek, A. CD19-specific chimeric T cell receptor. US7446179 (2008).
132. Campana, D., Imai, C. Chimeric receptors with 4-1BB stimulatory signaling domain. US8399645 B2 (2013).
133. June, C. H., Levine, B. L., Porter, D. L., Kalos, M. D. Use of chimeric antigen receptor-modified T cells to treat cancer. WO2012079000 (2012).
134. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119(12): 2709-20.
135. Cooper, L. J. N., Manuri, P., Olivares, S. Compositions and methods related to a human CD19-specific chimeric antigen receptor (h-CAR). WO2009091826 (2009).
136. Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: The role of imaging and rationale for systemic salvage targeted antiprostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012; 2012: 921674.
137. Congressionally Directed Medical Research Programs (CDMRP)/Department of Defence website. Available at: http://cdmrp. army. mil/pubs/video/pc/pdf/slovin_poster. pdf (Accessed on: May 19, 2013).
138. Sadelain, M., Brentjens, R., Maher, J. Nucleic acids encoding chimeric T cell receptors. US7446190 (2008).
139. Junghans, R. P. Antibodies as chimeric effector cell receptors against tumor antigens. US20070031438 (2007).
140. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered Tcells. Prostate 2007; 67(10): 1121-31.
141. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120(11): 3953-68.
142. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34(12): 1785-8.
143. Rosenberg, S. A., Chinnasamy, D. Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer. US20120213783 (2012) & WO2011041093 (2011).
144. June, C. H., Thompson, C. B., Nabel, G. J., Gray, G. S., Rennert, P. D. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells. US6352694 (2002).
145. June, C. H., Thompson, C. B., Nabel, G. J., Gray, G. S., Rennert, P. D., Freeman, G. J. Methods for selectively stimulating proliferation of T cells. US5858358 (1999).
146. June, C. H., Thompson, C. B., Nabel, G. J., Gray, G. S., Rennert, P. D. Methods for selectively stimulating proliferation of T cells. US6534055 (2003), US6887466 (2005), US6905681 (2005), US7144575 (2006) & US7175843 (2007).
147. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12(20 Pt 1): 6106-15.
148. Lavallee LT, Breau RH, Preston MA, Raju G, Morash C, Doucette S, et al. The association between tumour density and prostate cancer recurrence following radical prostatectomy. Can Urol Assoc J 2011; 5(6): 397-401.
149. Saad F, Hotte SJ. Guidelines for the management of castrateresistant prostate cancer. Can Urol Assoc J 2010; 4(6): 380-4.
150. Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012; 3: 73.
151. Garcia JA. Sipuleucel-T in patients with metastatic castrationresistant prostate cancer: An insight for oncologists. Ther Adv Med Oncol 2011; 3(2): 101-8.
152. Pal SK, Sartor O. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011; 13(5): 683-9.
153. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411-22.
154. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18(7): 1001-11.
155. Lum, L. G., Elfenbein, G. In situ immunization. US7763243 (2010).
156. Axelsen JB, Lotem J, Sachs L, Domany E. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci USA 2007; 104(32): 13122-7.